The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350000, China
Location status: Recruiting
Location contact
Jianxin Wan, doctor
CONTACT
Yi Chen, doctor
CONTACT
NCT Number: NCT06233838
To evaluate the decreasing rate of blood IL-6, β2-MG and PTH in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Fuzhou, Fujian, 350000, China
Location status: Recruiting
Jianxin Wan, doctor
CONTACT
Yi Chen, doctor
CONTACT
394 patients with maintenance hemodialysis were included in the study, and the blood purification time was ≥8 hours per week (including routine hemodialysis, high-throughput hemodialysis, hemodialysis filtration, hemoperfusion, etc.). Randomly assign the control group (197 cases) to receive hemodialysis or hemodialysis filtration treatment, and the frequency of treatment is ≥2 times/week; The experimental group (197 cases) were randomly assigned to receive Jianfan KHA80 hemoperfusion treatment on the basis of hemodialysis or hemodiafiltration treatment, and the frequency of hemoperfusion treatment was ≥2 times/month. The follow-up data of 0, 4, 12, 24, 36 and 52 weeks of treatment in the two groups were collected, and the information of combined medication and adverse events was also collected.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
Time frame: in the 52nd week
the rate of change of IL-6, β2-MG and PTH in the 52nd week of maintenance hemodialysis patients compared with routine hemodialysis.
First Affiliated Hospital of Fujian Medical University
Other
Prospective, Multicenter, Randomized, Open Label Study on the Efficacy and Safety of Comparison of KHA80 Blood Perfusion Combined With Hemodialysis and Conventional Hemodialysis in Clearing IL-6, β2-MG and PTH in Maintenance Hemodialysis Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03629977
Acute Kidney Injury, Critical Illness
Stockholm, Sweden
View Trial DetailsNCT05076318
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Aarhus N, Denmark
View Trial DetailsNCT06875115
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Dalin, Chiayi, Taiwan
View Trial DetailsNCT04768309
CKD, Female Urogenital Diseases
Pierre-Bénite, Rhône, France
View Trial Details